CompletedPhase 2NCT00062114

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Studying Plasmablastic lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alliance for Clinical Trials in Oncology
Principal Investigator
Thomas C. Shea, MD
UNC Lineberger Comprehensive Cancer Center
Intervention
rituximab(biological)
Enrollment
84 target
Eligibility
18 years · All sexes
Timeline
20042007

Study locations (30)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00062114 on ClinicalTrials.gov

Other trials for Plasmablastic lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Plasmablastic lymphoma

← Back to all trials